|
1
|
Byrd JC and Bresalier RS: Mucins and mucin
binding proteins in colorectal cancer. Cancer Metastasis Rev.
23:77–99. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dube DH and Bertozzi CR: Glycans in cancer
and inflammation-potential for therapeutics and diagnostics. Nat
Rev Drug Discov. 4:477–488. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pinho SS and Reis CA: Glycosylation in
cancer: Mechanisms and clinical implications. Nat Rev Cancer.
15:540–555. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Freire-de-Lima L, Gelfenbeyn K, Ding Y,
Mandel U, Clausen H, Handa K and Hakomori SI: Involvement of
O-glycosylation defining oncofetal fibronectin in
epithelial-mesenchymal transition process. Proc Natl Acad Sci USA.
108:17690–17695. 2001. View Article : Google Scholar
|
|
6
|
Brockhausen I: Mucin-type O-glycans in
human colon and breast cancer: Glycodynamics and functions. EMBO
Rep. 7:599–604. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Itzkowitz SH, Yuan M, Montgomery CK,
Kjeldsen T, Takahashi HK, Bigbee WL and Kim YS: Expression of Tn,
sialosyl-Tn, and T antigens in human colon cancer. Cancer Res.
49:197–204. 1989.PubMed/NCBI
|
|
8
|
Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng
Y and Chen H: Tumor-associated antigens: Tn antigen, sTn antigen,
and T antigen. HLA. 88:275–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meichenin M, Rocher J, Galanina O, Bovin
N, Nifantev N, Sherman A, Cassagnau E, Heymann MF, Bara J, Fraser
RH and Le Pendu J: Tk, a new colon tumor-associated antigen
resulting from altered O-glycosylation. Cancer Res. 60:5499–5507.
2000.PubMed/NCBI
|
|
10
|
Medina M, Vélez D, Asenjo JA, Egea G, Real
FX, Gil J and Subiza JL: Human colon adenocarcinomas express a
MUC1-associated novel carbohydrate epitope on core mucin glycans
defined by a monoclonal antibody (A10) raised against murine
Ehrlich tumor cells. Cancer Res. 59:1061–1070. 1999.PubMed/NCBI
|
|
11
|
Tarp MA and Clausen H: Mucin-type
O-glycosylation and its potential use in drug and vaccine
development. Biochim Biophys Acta. 1780:546–563. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kimura T, McKolanis JR, Dzubinski LA,
Islam K, Potter DM, Salazar AM, Schoen RE and Finn OJ: MUC1 vaccine
for individuals with advanced adenoma of the colon: A cancer
immunoprevention feasibility study. Cancer Prev Res (Phila).
6:18–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bennett EP, Mandel U, Clausen H, Gerken
TA, Fritz TA and Tabak LA: Control of mucin-type O-glycosylation: A
classification of the polypeptide GalNAc-transferase gene family.
Glycobiology. 22:736–756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van den Steen P, Rudd PM, Dwek RA and
Opdenakker G: Concepts and principles of O-linked glycosylation.
Crit Rev Biochem Mol Biol. 33:151–208. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Johansson ME, Larsson JM and Hansson GC:
The two mucus layers of colon are organized by the MUC2 mucin,
whereas the outer layer is a legislator of host-microbial
interactions. Proc Natl Acad Sci USA. 108 Suppl 1:S4659–S4665.
2011. View Article : Google Scholar
|
|
16
|
Brockhausen I, Schachter H and Stanley P:
Chapter 9 O-GalNAc glycansEssentials of Glycobiology. 2nd edition.
Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR,
Hart GW and Etxler ME: Cold Spring Harbor, New York: Laboratory
Press; 2009
|
|
17
|
Xia L: Core 3-derived O-glycans are
essential for intestinal mucus barrier function. Methods Enzymol.
479:123–141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holst S, Wuhrer M and Rombouts Y:
Glycosylation characteristics of colorectal cancer. Adv Cancer Res.
126:203–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bergstrom K, Liu X, Zhao Y, Gao N, Wu Q,
Song K, Cui Y, Li Y, McDaniel JM, McGee S, et al: Defective
intestinal mucin-type O-glycosylation causes spontaneous
colitis-associated cancer in mice. Gastroenterology.
151:152–164.e11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu J, Wei B, Wen T, Johansson ME, Liu X,
Bradford E, Thomsson KA, McGee S, Mansour L, Tong M, et al: Loss of
intestinal core 1-derived O-glycans causes spontaneous colitis in
mice. J Clin Invest. 121:1657–1666. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishida A, Lau CW, Zhang M, Andoh A, Shi
HN, Mizoguchi E and Mizoguchi A: The membrane-bound mucin Muc1
regulates T helper 17-cell responses and colitis in mice.
Gastroenterology. 142:865–874.e2. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Velcich A, Yang W, Heyer J, Fragale A,
Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K and
Augenlicht L: Colorectal cancer in mice genetically deficient in
the mucin Muc2. Science. 295:1726–1729. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
An G, Wei B, Xia B, McDaniel JM, Ju T,
Cummings RD, Braun J and Xia L: Increased susceptibility to colitis
and colorectal tumors in mice lacking core 3-derived O-glycans. J
Exp Med. 204:1417–1429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guda K, Moinova H, He J, Jamison O, Ravi
L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, et al:
Inactivating germ-line and somatic mutations in polypeptide
N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc
Natl Acad Sci USA. 106:12921–12925. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Venkitachalam S and Guda K: Altered
glycosyltransferases in colorectal cancer. Expert Rev Gastroenterol
Hepatol. 11:5–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mandel U, Hassan H, Therkildsen MH,
Rygaard J, Jakobsen MH, Juhl BR, Dabelsteen E and Clausen H:
Expression of polypeptide GalNAc-transferases in stratified
epithelia and squamous cell carcinomas: Immunohistological
evaluation using monoclonal antibodies to three members of the
GalNAc-transferase family. Glycobiology. 9:43–52. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Berois N, Mazal D, Ubillos L, Trajtenberg
F, Nicolas A, Sastre-Garau X, Magdelenat H and Osinaga E:
UDP-N-acetyl-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase-6 as a new immunohistochemical
breast cancer marker. J Histochem Cytochem. 54:317–328. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang
B, Song W, Ma S, Ge J, Deng H and Zhu M:
N-Acetylgalactosaminyltransferase-14 as a potential biomarker for
breast cancer by immunohistochemistry. BMC Cancer. 10:1232010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hussain MR, Hoessli DC and Fang M:
N-acetylgalacto-saminyltransferases in cancer. Oncotarget.
7:54067–54081. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taniuchi K, Cerny RL, Tanouchi A, Kohno K,
Kotani N, Honke K, Saibara T and Hollingsworth MA: Overexpression
of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell
growth. Oncogene. 30:4843–5484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu C, Oyama T, Osaki T, Li J, Takenoyama
M, Izumi H, Sugio K, Kohno K and Yasumoto K: Low expression of
polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung
adenocarcinoma: Impact on poor prognosis and early recurrence. Br J
Cancer. 90:436–442. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao S, Guo T, Li J, Uramoto H, Guan H,
Deng W and Gu C: Expression and prognostic value of GalNAc-T3 in
patients with completely resected small (≤2 cm) peripheral lung
adenocarcinoma after IASLC/ATS/ERS classification. Onco Targets
Ther. 8:3143–3152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyahara N, Shoda J, Kawamoto T, Furukawa
M, Ueda T, Todoroki T, Tanaka N, Matsuo K, Yamada Y, Kohno K and
Irimura T: Expression of
UDP-N-acetyl-alpha-D-galactosamine-polypeptide
N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer
correlates with postsurgical survival of pathological tumor stage 2
carcinoma of the gallbladder. Clin Cancer Res. 10:2090–2099. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He H, Shen Z, Zhang H, Wang X, Tang Z, Xu
J and Sun Y: Clinical significance of polypeptide
N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in
patients with gastric cancer. Br J Cancer. 110:2021–2029. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee ES, Son DS, Kim SH, Lee J, Jo J, Han
J, Kim H, Lee HJ, Choi HY, Jung Y, et al: Prediction of
recurrence-free survival in postoperative non-small cell lung
cancer patients by using an integrated model of clinical
information and gene expression. Clin Cancer Res. 14:7397–7404.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kwon OS, Oh E, Park JR, Lee JS, Bae GY,
Koo JH, Kim H, Choi YL, Choi YS, Kim J and Cha HJ: GalNAc-T14
promotes metastasis through Wnt dependent HOXB9 expression in lung
adenocarcinoma. Oncotarget. 6:41916–41928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Freire T, Berois N, Sóñora C, Varangot M,
Barrios E and Osinaga E: UDP-N-acetyl-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a
potential new marker for detection of bone marrow-disseminated
breast cancer cells. Int J Cancer. 119:1383–1388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Berois N, Blanc E, Ripoche H, Mergui X,
Trajtenberg F, Cantais S, Barrois M, Dessen P, Kågedal B, Bénard J,
et al: ppGalNAc-T13: A new molecular marker of bone marrow
involvement in neuroblastoma. Clin Chem. 52:1701–1172. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Berois N, Gattolliat CH, Barrios E,
Capandeguy L, Douc-Rasy S, Valteau-Couanet D, Bénard J and Osinaga
E: GALNT9 gene expression is a prognostic marker in neuroblastoma
patients. Clin Chem. 59:225–233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kohsaki T, Nishimori I, Nakayama H,
Miyazaki E, Enzan H, Nomoto M, Hollingsworth MA and Onishi S:
Expression of UDP-GalNAc:polypeptide
N-acetylgalactosaminyltransferase isozymes T1 and T2 in human
colorectal cancer. J Gastroenterol. 35:840–848. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bennett EP, Hassan H and Clausen H: cDNA
cloning and expression of a novel human
UDP-N-acetyl-alpha-D-galactosamine. Polypeptide
N-acetylgalactosaminyltransferase, GalNAc-t3. J Biol Chem.
271:17006–17012. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo JM, Chen HL, Wang GM, Zhang YK and
Narimatsu H: Expression of UDP-GalNAc:polypeptide
N-acetyl-galactosaminyltransferase-12 in gastric and colonic cancer
cell lines and in human colorectal cancer. Oncology. 67:271–276.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kato K, Takeuchi H, Kanoh A, Miyahara N,
Nemoto-Sasaki Y, Morimoto-Tomita M, Matsubara A, Ohashi Y, Waki M,
Usami K, et al: Loss of UDP-GalNAc:polypeptide
N-acetyl-galactosaminyltransferase 3 and reduced O-glycosylation in
colon carcinoma cells selected for hepatic metastasis. Glycoconj J.
27:267–276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shibao K, Izumi H, Nakayama Y, Ohta R,
Nagata N, Nomoto M, Matsuo K, Yamada Y, Kitazato K, Itoh H and
Kohno K: Expression of
UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc
N-acetylgalactosaminyl transferase-3 in relation to differentiation
and prognosis in patients with colorectal carcinoma. Cancer.
94:1939–1946. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kato K, Takeuchi H, Kanoh A, Mandel U,
Hassan H, Clausen H and Irimura T: N-acetylgalactosamine
incorporation into a peptide containing consecutive threonine
residues by UDP-N-acetyl-D-galactosaminide:polypeptide
N-acetylgalactosaminyltransferases. Glycobiology. 11:821–829. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kanoh A, Takeuchi H, Kato K, Waki M, Usami
K and Irimura T: Interleukin-4 induces specific pp-GalNAc-T
expression and alterations in mucin O-glycosylation in colonic
epithelial cells. Biochim Biophys Acta. 1780:577–584. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bennett EP, Hassan H, Mandel U,
Hollingsworth MA, Akisawa N, Ikematsu Y, Merkx G, van Kessel AG,
Olofsson S and Clausen H: Cloning and characterization of a close
homologue of human UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6.
Evidence for genetic but not functional redundancy. J Biol Chem.
274:25362–15370. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brooks SA, Carter TM, Bennett EP, Clausen
H and Mandel U: Immunolocalisation of members of the polypeptide
N-acetyl-galactosaminyl transferase (ppGalNAc-T) family is
consistent with biologically relevant altered cell surface
glycosylation in breast cancer. Acta Histochem. 109:273–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Patani N, Jiang W and Mokbel K: Prognostic
utility of glycosyltransferase expression in breast cancer. Cancer
Genomics Proteomics. 5:333–340. 2008.PubMed/NCBI
|
|
50
|
Park JH, Nishidate T, Kijima K, Ohashi T,
Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T:
Critical roles of mucin 1 glycosylation by transactivated
polypeptide N-acetylgalactosaminyltransferase 6 in mammary
carcinogenesis. Cancer Res. 70:2759–2769. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Park JH, Katagiri T, Chung S, Kijima K and
Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6
disrupts mammary acinar morphogenesis through O-glycosylation of
fibronectin. Neoplasia. 13:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li Z, Yamada S, Wu Y, Wang KY, Liu YP,
Uramoto H, Kohno K and Sasaguri Y: Polypeptide
N-acetylgalactosaminyltransferase-6 expression independently
predicts poor overall survival in patients with lung adenocarcinoma
after curative resection. Oncotarget. 7:54463–54473.
2016.PubMed/NCBI
|
|
53
|
Li Z, Yamada S, Inenaga S, Imamura T, Wu
Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K and Sasaguri Y:
Polypeptide N-acetylgalactosaminyltransferase 6 expression in
pancreatic cancer is an independent prognostic factor indicating
better overall survival. Br J Cancer. 104:1882–1889. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kitada S, Yamada S, Kuma A, Ouchi S,
Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R,
et al: Polypeptide N-acetylgalactosaminyl transferase 3
independently predicts high-grade tumours and poor prognosis in
patients with renal cell carcinomas. Br J Cancer. 109:472–481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang ZQ, Bachvarova M, Morin C, Plante M,
Gregoire J, Renaud MC, Sebastianelli A and Bachvarov D: Role of the
polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer
progression: Possible implications in abnormal mucin
O-glycosylation. Oncotarget. 5:544–560. 2014.PubMed/NCBI
|
|
56
|
Onitsuka K, Shibao K, Nakayama Y, Minagawa
N, Hirata K, Izumi H, Matsuo K, Nagata N, Kitazato K, Kohno K and
Itoh H: Prognostic significance of
UDP-N-acetyl-alpha-D-galactosamine: polypeptide
N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in
patients with gastric carcinoma. Cancer Sci. 94:32–36. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gill DJ, Chia J, Senewiratne J and Bard F:
Regulation of O-glycosylation through Golgi-to-ER relocation of
initiation enzymes. J Cell Biol. 189:843–858. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Punt CJ, Koopman M and Vermeulen L: From
tumour heterogeneity to advances in precision treatment of
colorectal cancer. Nat Rev Clin Oncol. 14:235–246. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mahasneh A, Al-Shaheri F and Jamal E:
Molecular biomarkers for an early diagnosis, effective treatment
and prognosis of colorectal cancer: Current updates. Exp Mol
Pathol. 102:475–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sinicrope FA, Okamoto K, Kasi PM and
Kawakami H: Molecular biomarkers in the personalized treatment of
colorectal cancer. Clin Gastroenterol Hepatol. 14:651–658. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dienstmann R, Salazar R and Tabernero J:
Personalizing colon cancer adjuvant therapy: Selecting optimal
treatments for individual patients. J Clin Oncol. 33:1787–1796.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lavrsen K, Dabelsteen S, Vakhrushev SY,
Levann AMR, Haue AD, Dylander A, Mandel U, Hansen L, Frödin M,
Bennett EP and Wandall HH: De novo expression of human polypeptide
N-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon
adenocarcinoma inhibits the differentiation of colonic epithelium.
J Biol Chem. 293:1298–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Andre T, de Gramont A, Vernerey D,
Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T,
Tabernero J, Van Laethem JL, et al: Adjuvant fluorouracil,
leucovorin, and oxaliplatin in stage II to III colon cancer:
Updated 10-year survival and outcomes according to BRAF mutation
and mismatch repair status of the MOSAIC study. J Clin Oncol.
33:4176–4187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Verhoeff SR, van Erning FN, Lemmens VE, de
Wilt JH and Pruijt JF: Adjuvant chemotherapy is not associated with
improved survival for all high-risk factors in stage II colon
cancer. Int J Cancer. 139:187–193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
